Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Novavax revenue
Novavax's revenue is $682.2 million.
What is Novavax's revenue?
- Novavax's revenue growth from 2010 to 2024 is 198,781.05%.
- Novavax has 791 employees, and the revenue per employee ratio is $862,404.
- Novavax's peak quarterly revenue was $628.2M in 2022(q3).
- Novavax peak revenue was $2.0B in 2022.
- Novavax annual revenue for 2023 was 983.7M, -50.36% growth from 2022.
- Novavax annual revenue for 2024 was 682.2M, -30.65% growth from 2023.
On this page
Zippia finds jobs where you're a top candidate and applies on your behalf.
Novavax historical revenue
Novavax's peak revenue was $2.0B in 2022. The peak quarterly revenue was $628.2M in 2022(q3).
Novavax's revenue increased from $343.0k in 2010 to $682.2M currently. That's a 198,781.05% change in annual revenue.
Novavax annual revenue
Novavax annual revenue over time
| Fiscal year / year | Novavax revenue |
|---|---|
| 2010 | $343,000 |
| 2011 | $14.7M |
| 2012 | $22.1M |
| 2013 | $20.9M |
| 2014 | $30.7M |
| 2015 | $36.3M |
| 2016 | $15.4M |
| 2017 | $31.2M |
| 2018 | $34.3M |
| 2019 | $18.7M |
| 2020 | $475.6M |
| 2021 | $1.1B |
| 2022 | $2.0B |
| 2023 | $983.7M |
| 2024 | $682.2M |
Rate Novavax's financial transparency
Novavax annual growth
Novavax saw the greatest revenue growth in 2011, when revenue increased by 4,182.22%.
Novavax had the lowest revenue growth in 2016, when revenue changed by -57.65%.
Novavax annual growth rate over time
| Year | Novavax growth |
|---|---|
| 2011 | 4182%↑ |
| 2012 | 50%↑ |
| 2013 | -5%↓ |
| 2014 | 47%↑ |
| 2015 | 18%↑ |
| 2016 | -58%↓ |
| 2017 | 103%↑ |
| 2018 | 10%↑ |
| 2019 | -46%↓ |
| 2020 | 2448%↑ |
| 2021 | 141%↑ |
| 2022 | 73%↑ |
| 2023 | -50%↓ |
| 2024 | -31%↓ |
Novavax quarterly revenue over time
- Q1
- Q2
- Q3
- Q4
Novavax quarterly growth rate over time
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2011 | - | $3.0M | $5.0M | $5.8M |
| 2012 | $4.6M | $7.1M | $5.8M | $4.6M |
| 2013 | $3.8M | $3.5M | $4.8M | $8.7M |
| 2014 | $7.5M | $8.3M | $8.2M | $6.7M |
| 2015 | $9.9M | $14.0M | $6.5M | $5.9M |
| 2016 | $4.2M | $2.5M | $3.2M | $5.4M |
| 2017 | $5.7M | $6.7M | $8.4M | $10.4M |
| 2018 | $9.7M | $10.8M | $7.7M | $6.1M |
| 2019 | $4.0M | $3.4M | $2.5M | $8.8M |
| 2020 | $3.4M | $35.5M | $157.0M | ($173.4M) |
| 2021 | $447.2M | $298.0M | $178.8M | ($726.5M) |
| 2022 | $604.6M | $185.9M | $628.2M | $288.1M |
| 2023 | ($6.4M) | $424.4M | $22.0M | $253.1M |
| 2024 | $93.9M | $415.5M | $84.5M | $88.3M |
Novavax jobs nearby
Do you work at Novavax?
Did Novavax meet its revenue projections?
Novavax financial information
| CEO | Richard Maradie |
| Industry | Pharmaceuticals, Biotechnology & Life Sciences |
| Company Type | Public |
| Employees Number | 791 |
| Date Founded | 1987 |
| Headquarters | Gaithersburg, Maryland |
| Number of Locations | 3 |
| Revenue | $682.2M |
| Net Income | -$657,939,000 |
| Gross Proft | $479.4M (2024) |
| PE Ratio | -4.35 |
| Tax Rate | -0.1% |
| Market Capitalization | $815.5M |
| Total Assets | $2,258,679,000 |
| Ticker | NVAX |
Novavax jobs you might like
Novavax financing
Novavax received early financing of $5.0M on 2008-06-27.
| Series | Round size | Date |
|---|---|---|
| Post Ipo Equity | $5M | 06/2008 |
| Post Ipo Equity | $94.6M | 09/2013 |
| Grant | $89M | 09/2015 |
| Grant | $4M | 03/2020 |
| Grant | $384M | 05/2020 |
| Post Ipo Equity | $200M | 06/2020 |
| Grant | $1.6B | 07/2020 |
Novavax investors
| Investors | Security type |
|---|---|
| Innovations Kapital | Post Ipo Equity |
| Bill & Melinda Gates Foundation | Grant |
| Coalition for Epidemic Preparedness Innovations | Grant |
| Coalition for Epidemic Preparedness Innovations | Grant |
| RA Capital Management | Post Ipo Equity |
| United States Federal Government | Grant |
Novavax competitors
Novavax's top competitor, Johnson & Johnson, earned an annual revenue of $88.8B.
Novavax's smallest competitor is INOVIO Pharmaceuticals with revenue of $217.8K last year.
| Company name | Average salary | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Gilead Sciences | $99,828 | $28.8B | 11,800 | 774 |
| Regeneron | $85,589 | $14.2B | 9,123 | 357 |
| Seagen | $85,008 | $2.0B | 900 | - |
| Emergent BioSolutions | $77,521 | $1.6B | 1,834 | 6 |
| Human Genome Sciences | $70,157 | $131.0M | 1,000 | - |
| Merck | $90,328 | $64.2B | 74,000 | 1,347 |
| Med Immune Inc | $56,355 | $1.7B | 5,000 | - |
| Johnson & Johnson | $76,686 | $88.8B | 134,500 | 1,328 |
| Vertex Pharmaceuticals | $95,952 | $11.0B | 3,400 | 247 |
| Pfizer | $70,868 | $63.6B | 78,500 | 412 |
Search for jobs
Related company revenues
Working at related companies
Related company jobs
Novavax highest paying jobs
Zippia gives an in-depth look into the details of Novavax, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Novavax. The employee data is based on information from people who have self-reported their past or current employments at Novavax. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Novavax. The data presented on this page does not represent the view of Novavax and its employees or that of Zippia.
Novavax may also be known as or be related to Novavax, Novavax AB, Novavax Inc, Novavax Inc. and Novavax, Inc.